Trial Profile
A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Avadomide (Primary) ; Onatasertib (Primary) ; Rituximab (Primary) ; Spebrutinib (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 16 Jan 2024 Status changed from active, no longer recruiting to discontinued. (Replaced with another clinical trial.)
- 10 Nov 2023 Planned End Date changed from 31 Oct 2023 to 31 Jan 2024.
- 10 Nov 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Jan 2024.